Medical big guns help Proteomics rev up Aussie cancer test rollout

The board includes leading UK surgeon Professor Hugh Barr, chief investigator of the landmark Barrett’s Oesophagus Surveillance Study, and his Barrett’s colleague Professor Krish Ragunath, a specialist in oesophageal management.

The group also includes the Dutch pioneer in oesophageal cancer imaging and biomarker development, Professor Jacques Bergman, and United States-based thoracic surgeon Professor Andrew Chang, Mayo Clinic AI researcher and gastroenterologist Professor Prasad Iyer, keyhole surgery specialist Dr Daniela Molena and pathologist Dr Robert Odze.

Proteomics International managing director Dr Richard Lipscombe said: “Their expertise and clinical insights will be invaluable as we introduce PromarkerEso to global markets and strive to make a meaningful impact on the lives of people living with chronic acid reflux.”

With market-ready technology, regulatory runs on the board and now a world-class advisory team in its corner, the company has firmly planted its flag as a frontrunner in early cancer detection and precision medicine – potentially saving lives in the process.

Is your ASX-listed company doing something interesting? Contact: [email protected]